Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Si-Wei-Qing-Gan-Tang (SWQGT) is a traditional Chinese medicine formula used as a folk remedy herbal tea, primarily in the Ganzhou region of Jiangxi province, China, for the treatment of chronic hepatitis and non-alcoholic steatohepatitis (NASH). It exerts its therapeutic effects by modulating the Nuclear Factor-κB (NF-κB) signaling pathway and inducing autophagy. Research indicates that SWQGT reduces hepatic inflammation by decreasing levels of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. It also inhibits the phosphorylation of p38 MAPK, MEK1/2, and ERK1/2, and suppresses the mTOR pathway while activating ULK1 and LC3II to promote autophagic flux, thereby improving hepatic steatosis and pathological liver changes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Si-Wei-Qing-Gan-Tang.